eFFECTOR Therapeutics, Inc. (EFTR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -33.73 Million USD | -4.1% |
| 2022 | -32.4 Million USD | -1.59% |
| 2021 | -31.89 Million USD | -298.67% |
| 2020 | 16.05 Million USD | 156.74% |
| 2019 | -28.29 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -8.36 Million USD | 2.32% |
| 2023 Q3 | -8.3 Million USD | -9.03% |
| 2023 FY | - USD | -4.1% |
| 2023 Q4 | -8.56 Million USD | -3.18% |
| 2023 Q2 | -7.61 Million USD | 20.14% |
| 2023 Q1 | -9.53 Million USD | -9.32% |
| 2022 Q4 | -8.72 Million USD | 3.65% |
| 2022 Q1 | -7.2 Million USD | 41.91% |
| 2022 Q3 | -9.05 Million USD | -17.71% |
| 2022 FY | - USD | -1.59% |
| 2022 Q2 | -7.69 Million USD | -6.75% |
| 2021 FY | - USD | -298.67% |
| 2021 Q3 | -8.41 Million USD | -66.08% |
| 2021 Q2 | -5.06 Million USD | 12.27% |
| 2021 Q1 | -5.77 Million USD | -4.9% |
| 2021 Q4 | -12.4 Million USD | -47.36% |
| 2020 Q3 | -7.26 Million USD | -179.41% |
| 2020 Q4 | -5.5 Million USD | 24.17% |
| 2020 FY | - USD | 156.74% |
| 2020 Q1 | 19.64 Million USD | 0.0% |
| 2020 Q2 | 9.14 Million USD | -53.46% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -7441.606% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -14.326% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 70.424% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -114.028% |
| Better Therapeutics, Inc. | -38.26 Million USD | 11.837% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 11.844% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -88.594% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -1.079% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 68.28% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -3592.829% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -3.851% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 27.754% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -493.499% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -106.936% |
| Molecular Templates, Inc. | 1.43 Million USD | 2458.951% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -143.119% |
| NexImmune, Inc. | -28.16 Million USD | -19.759% |
| Orgenesis Inc. | -60.71 Million USD | 44.443% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 34.236% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -45847.75% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -108.934% |
| Scopus BioPharma Inc. | -11.71 Million USD | -187.993% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 93.752% |
| Statera Biopharma, Inc. | 38.93 Million USD | 186.639% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -390.02% |
| Trevena, Inc. | -35.28 Million USD | 4.407% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -60082.691% |
| Vaccinex, Inc. | -19.74 Million USD | -70.817% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3121.94% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 28.016% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -364.449% |